Olutasidenib is a safer drug. Check RIGL. Still buying opportunity. Both drugs are approved. Huge advantage over Tusp. We know ORR, mDoR, mPFS, mOS for them and we have no idea how it looks like for Tusp in IDHmut population. Maybe Tusp is inferior drug and milder safety profile, if true, is worthless.
News 
Market Data 
Discover 
AI
